210 related articles for article (PubMed ID: 23275065)
21. Catalytic site-directed gamma-secretase complex inhibitors do not discriminate pharmacologically between Notch S3 and beta-APP cleavages.
Lewis HD; Pérez Revuelta BI; Nadin A; Neduvelil JG; Harrison T; Pollack SJ; Shearman MS
Biochemistry; 2003 Jun; 42(24):7580-6. PubMed ID: 12809514
[TBL] [Abstract][Full Text] [Related]
22. Gamma secretase inhibition: Effects on fertility and embryo-fetal development in rats.
Sivaraman L; Sanderson T
Toxicol Appl Pharmacol; 2023 Jun; 469():116512. PubMed ID: 37030625
[TBL] [Abstract][Full Text] [Related]
23. Inhibition of amyloid beta-peptide production by blockage of beta-secretase cleavage site of amyloid precursor protein.
Na CH; Jeon SH; Zhang G; Olson GL; Chae CB
J Neurochem; 2007 Jun; 101(6):1583-95. PubMed ID: 17542811
[TBL] [Abstract][Full Text] [Related]
24. Proton myo-inositol cotransporter is a novel γ-secretase associated protein that regulates Aβ production without affecting Notch cleavage.
Teranishi Y; Inoue M; Yamamoto NG; Kihara T; Wiehager B; Ishikawa T; Winblad B; Schedin-Weiss S; Frykman S; Tjernberg LO
FEBS J; 2015 Sep; 282(17):3438-51. PubMed ID: 26094765
[TBL] [Abstract][Full Text] [Related]
25. Inhibition of γ-Secretase Leads to an Increase in Presenilin-1.
Sogorb-Esteve A; García-Ayllón MS; Llansola M; Felipo V; Blennow K; Sáez-Valero J
Mol Neurobiol; 2018 Jun; 55(6):5047-5058. PubMed ID: 28815510
[TBL] [Abstract][Full Text] [Related]
26. Oral administration of a potent and selective non-peptidic BACE-1 inhibitor decreases beta-cleavage of amyloid precursor protein and amyloid-beta production in vivo.
Hussain I; Hawkins J; Harrison D; Hille C; Wayne G; Cutler L; Buck T; Walter D; Demont E; Howes C; Naylor A; Jeffrey P; Gonzalez MI; Dingwall C; Michel A; Redshaw S; Davis JB
J Neurochem; 2007 Feb; 100(3):802-9. PubMed ID: 17156133
[TBL] [Abstract][Full Text] [Related]
27. A contrast in safety, pharmacokinetics and pharmacodynamics across age groups after a single 50 mg oral dose of the γ-secretase inhibitor avagacestat.
Tong G; Wang JS; Sverdlov O; Huang SP; Slemmon R; Croop R; Castaneda L; Gu H; Wong O; Li H; Berman RM; Smith C; Albright CF; Dockens R
Br J Clin Pharmacol; 2013 Jan; 75(1):136-45. PubMed ID: 22616739
[TBL] [Abstract][Full Text] [Related]
28. Decrease in brain soluble amyloid precursor protein β (sAPPβ) in Alzheimer's disease cortex.
Wu G; Sankaranarayanan S; Hsieh SH; Simon AJ; Savage MJ
J Neurosci Res; 2011 Jun; 89(6):822-32. PubMed ID: 21433051
[TBL] [Abstract][Full Text] [Related]
29. Inhibiting β-secretase activity in Alzheimer's disease cell models with single-chain antibodies specifically targeting APP.
Boddapati S; Levites Y; Sierks MR
J Mol Biol; 2011 Jan; 405(2):436-47. PubMed ID: 21073877
[TBL] [Abstract][Full Text] [Related]
30. In vivo characterization of Abeta(40) changes in brain and cerebrospinal fluid using the novel gamma-secretase inhibitor N-[cis-4-[(4-chlorophenyl)sulfonyl]-4-(2,5-difluorophenyl)cyclohexyl]-1,1,1-trifluoromethanesulfonamide (MRK-560) in the rat.
Best JD; Jay MT; Otu F; Churcher I; Reilly M; Morentin-Gutierrez P; Pattison C; Harrison T; Shearman MS; Atack JR
J Pharmacol Exp Ther; 2006 May; 317(2):786-90. PubMed ID: 16443723
[TBL] [Abstract][Full Text] [Related]
31. Dynamics of Aβ42 reduction in plasma, CSF and brain of rats treated with the γ-secretase modulator, GSM-10h.
Hawkins J; Harrison DC; Ahmed S; Davis RP; Chapman T; Marshall I; Smith B; Mead TL; Medhurst A; Giblin GM; Hall A; Gonzalez MI; Richardson J; Hussain I
Neurodegener Dis; 2011; 8(6):455-64. PubMed ID: 21389687
[TBL] [Abstract][Full Text] [Related]
32. Proteolytic processing of the Alzheimer's disease amyloid precursor protein in brain and platelets.
Evin G; Zhu A; Holsinger RM; Masters CL; Li QX
J Neurosci Res; 2003 Nov; 74(3):386-92. PubMed ID: 14598315
[TBL] [Abstract][Full Text] [Related]
33. Safety and tolerability of the γ-secretase inhibitor avagacestat in a phase 2 study of mild to moderate Alzheimer disease.
Coric V; van Dyck CH; Salloway S; Andreasen N; Brody M; Richter RW; Soininen H; Thein S; Shiovitz T; Pilcher G; Colby S; Rollin L; Dockens R; Pachai C; Portelius E; Andreasson U; Blennow K; Soares H; Albright C; Feldman HH; Berman RM
Arch Neurol; 2012 Nov; 69(11):1430-40. PubMed ID: 22892585
[TBL] [Abstract][Full Text] [Related]
34. An amyloid-notch hypothesis for Alzheimer's disease.
Ethell DW
Neuroscientist; 2010 Dec; 16(6):614-7. PubMed ID: 20592273
[TBL] [Abstract][Full Text] [Related]
35. A presenilin-1-dependent gamma-secretase-like protease mediates release of Notch intracellular domain.
De Strooper B; Annaert W; Cupers P; Saftig P; Craessaerts K; Mumm JS; Schroeter EH; Schrijvers V; Wolfe MS; Ray WJ; Goate A; Kopan R
Nature; 1999 Apr; 398(6727):518-22. PubMed ID: 10206645
[TBL] [Abstract][Full Text] [Related]
36. Pharmacological and Toxicological Properties of the Potent Oral
Wagner SL; Rynearson KD; Duddy SK; Zhang C; Nguyen PD; Becker A; Vo U; Masliah D; Monte L; Klee JB; Echmalian CM; Xia W; Quinti L; Johnson G; Lin JH; Kim DY; Mobley WC; Rissman RA; Tanzi RE
J Pharmacol Exp Ther; 2017 Jul; 362(1):31-44. PubMed ID: 28416568
[TBL] [Abstract][Full Text] [Related]
37. Cerebrospinal fluid β-Amyloid turnover in the mouse, dog, monkey and human evaluated by systematic quantitative analyses.
Lu Y; Barton HA; Leung L; Zhang L; Hajos-Korcsok E; Nolan CE; Liu J; Becker SL; Wood KM; Robshaw AE; Taylor CK; O'Neill BT; Brodney MA; Riddell D
Neurodegener Dis; 2013; 12(1):36-50. PubMed ID: 22922480
[TBL] [Abstract][Full Text] [Related]
38. 1-(3',4'-Dichloro-2-fluoro[1,1'-biphenyl]-4-yl)-cyclopropanecarboxylic acid (CHF5074), a novel gamma-secretase modulator, reduces brain beta-amyloid pathology in a transgenic mouse model of Alzheimer's disease without causing peripheral toxicity.
Imbimbo BP; Del Giudice E; Colavito D; D'Arrigo A; Dalle Carbonare M; Villetti G; Facchinetti F; Volta R; Pietrini V; Baroc MF; Serneels L; De Strooper B; Leon A
J Pharmacol Exp Ther; 2007 Dec; 323(3):822-30. PubMed ID: 17895400
[TBL] [Abstract][Full Text] [Related]
39. Presenilin clinical mutations can affect gamma-secretase activity by different mechanisms.
Bentahir M; Nyabi O; Verhamme J; Tolia A; Horré K; Wiltfang J; Esselmann H; De Strooper B
J Neurochem; 2006 Feb; 96(3):732-42. PubMed ID: 16405513
[TBL] [Abstract][Full Text] [Related]
40. Acute effect on the Aβ isoform pattern in CSF in response to γ-secretase modulator and inhibitor treatment in dogs.
Portelius E; Van Broeck B; Andreasson U; Gustavsson MK; Mercken M; Zetterberg H; Borghys H; Blennow K
J Alzheimers Dis; 2010; 21(3):1005-12. PubMed ID: 20634579
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
